ABEO NASDAQ Week ended 31 Jul 2026

Weekly Investor Report

Abeona Therapeutics Inc · Healthcare · Biotechnology

Open interactive chart View report data
Latest close 6.42 USD
6.1% latest week
Weekly setup

Constructive, but selective

The weekly trend is active. Price is 17.8% above the Trend Line and sits at 68.4% of its 52-week range. The latest completed week returned 6.1%, after a 0.3% four-week move. The latest factor snapshot indicates quality is middle-of-the-pack; growth ranks strongly; valuation is neither clearly cheap nor expensive. Options positioning is mixed with 43/100 conviction, while the latest news-sentiment score is 49/100. Near-term considerations: volume confirmation is below normal; earnings are due in 12d.

Setup score 59 out of 100
Latest Close 6.42 USD 31 Jul 2026
1W Return 6.1% latest completed week
4W Return 0.3% short-term follow-through
12W Return 8.8% quarterly tape
Trend Breadth 40.4% 21 of 52 weeks active
Volume Ratio 0.8x vs 13-week average
What is working
  • The trend backdrop is active with a 14-week active streak.
  • Price is above the Trend Line, keeping the weekly tape constructive.
  • Price is above Fair Value, showing premium demand versus the model.
  • Activity pressure is positive on the latest completed week.
What could go wrong
  • No major top-level risk cluster is currently dominant.
What to watch next
  • Trend Line remains the key weekly regime level.
  • Activity pressure is the gauge to monitor for confirmation or fade.
  • A volume ratio above 1.5x would show stronger participation in the next move.
Price follow-through 6.1% Latest completed week; four-week move 0.3%. Indicator stack 67/76 Trend and activity pressure are weighted against the latest 12-week confirmation window. Trend backdrop Active The trend backdrop defines the current weekly regime. Patient Capital Quiet Activity-pressure buy-signal status for institutional accumulation timing. Options pressure Mixed 43/100 conviction; expected move 24.3%. News sentiment 49/100 51 relevant articles in the latest sentiment read. Event risk 12d Next report is scheduled for 13 Aug 2026; event risk rises as the date approaches.
01 · Price action

Where price is—and whether the trend supports it

The weekly trend is active. Price is 17.8% above the Trend Line and sits at 68.4% of its 52-week range. The latest completed week returned 6.1%, after a 0.3% four-week move.

Study the full chart

52-week price path

Price vs Trend Line and Fair Value
Price Trend Line Fair Value
02 · Volume and demand

Is real participation confirming the move?

Latest weekly volume is 0.8x the 13-week average. Participation is below its recent norm, so price strength is not receiving full volume confirmation.

26-week volume confirmation

Bar height shows volume; colour shows the weekly price direction
6 Feb 13 Feb 20 Feb 27 Feb 6 Mar 13 Mar 20 Mar 27 Mar 3 Apr 10 Apr 17 Apr 24 Apr 1 May 8 May 15 May 22 May 29 May 5 Jun 12 Jun 19 Jun 26 Jun 3 Jul 10 Jul 17 Jul 24 Jul 31 Jul
Up week Down week
Demand beneath price

Activity pressure and institutional-style signals

These indicators assess whether participation is improving beneath the headline price move. They are supporting evidence, not proof of institutional buying.

Activity pressure path

Latest 0.7912-week average 0.49

12-week confirmation

Trend active12/12Active trend-backdrop weeks in the latest 12-week window.
Positive pressure12/12Weeks with constructive activity pressure in the latest 12-week window.
Positive leadership5/12Weeks with positive relative leadership in the latest 12-week window.
Activity pressure0.79Current proprietary activity-pressure read.
Buy signals0Accumulation signal count in the latest 12 weeks.
Reversal markers0No reversal markers

No recent accumulation markers. No reversal markers.

03 · Momentum and leadership

Is performance persistent—and is the stock leading?

Performance is 0.3% over four weeks, 8.8% over 12 weeks, and -1.1% over one year. The current trend has remained active for 14 consecutive weeks.

Performance by holding period

1W6.1%
4W0.3%
12W8.8%
26W26.1%
52W-1.1%
Active trend streak14 weeks
Active weeks in one year21
Trend breadth40.4%

Activity pressure vs relative leadership

Activity pressureRelative leadership
Pressure1.36Latest activity-pressure read.
Pressure change20.8%Four-week change in activity pressure.
Leadership6.86Latest relative-leadership reading.
RS change499.0%Four-week change in relative leadership.
04 · Fundamentals and valuation

What investors are paying for—and the quality behind it

The latest factor snapshot indicates quality is middle-of-the-pack; growth ranks strongly; valuation is neither clearly cheap nor expensive.

Open full factor analysis
Factor week 26 Jul 2026 Financial statements through 31 Mar 2026 Field coverage 91% Model confidence 87%

Relative factor standing

Higher display scores are better. Each score is converted from the underlying universe rank, where rank 1 is best.

Overall factor strength72/100Blend of value, momentum, and quality. Underlying universe rank 29; rank 1 is best.
Value77/100Relative valuation strength. Underlying universe rank 24; rank 1 is best.
Quality66/100Profitability and accounting quality. Underlying universe rank 35; rank 1 is best.
Momentum20/100Medium-term price momentum. Underlying universe rank 81; rank 1 is best.
Growth91/100Revenue and earnings growth. Underlying universe rank 10; rank 1 is best.
How to read this

Quality and valuation are separate questions

A strong company can still carry a demanding valuation. This report shows profitability, growth, balance-sheet strength, and the price paid for those characteristics separately.

Value-quality framework97/100Value and quality alignment from the Sharemaestro SVQF framework.

Valuation

How much investors are paying for earnings, sales, and cash flow.

P/E
5.2x
Price divided by trailing earnings.
Price / sales
23.7x
Market value relative to trailing revenue.
EV / EBITDA
4.2x
Enterprise value relative to operating cash earnings.
Free-cash-flow yield
-22.9%
Free cash flow as a share of enterprise value.

Business quality

Margins and the return generated on invested capital.

Gross margin
51.9%
Gross profit retained from each unit of revenue.
Operating margin
480.1%
Operating profit retained from revenue.
Free-cash-flow margin
-482.9%
Free cash flow generated from revenue.
Return on invested capital
65.3%
Operating return generated on invested capital.

Growth and financial strength

Recent business growth and accounting strength.

Revenue growth
204.1%
Latest one-year revenue growth.
EPS growth
-
Latest one-year earnings-per-share growth.
Free-cash-flow growth
-
Latest one-year free-cash-flow growth.
Piotroski F-score
4/9
Nine-point accounting-strength checklist.

Shareholder return and balance sheet

Cash returned to owners and financial leverage.

Dividend yield
-
Cash dividends relative to market value.
Buyback yield
-3.0%
Net share repurchases relative to market value.
Shareholder yield
-3.0%
Dividend yield plus net buyback yield.
Net debt / EBITDA
-0.5x
Balance-sheet debt relative to operating cash earnings.
05 · Ownership, options, and sentiment

What other market participants are doing

Options, insider transactions, market sentiment, and activity-pressure signals can confirm or challenge the price story. None should be used alone.

Options positioningMixed

ABEO shows mixed options pressure with a 43/100 conviction score, put-call volume ratio of 1.20, expected move of 24.3%, and Sharemaestro trend signal active.

Conviction43/100
Expected move24.3%
Put/call volume1.20
Pressure0
Speculation42
Volatility96
Trend agreement93
Open options detail
Insider activity0 / 20

0 acquisitions and 20 disposals in the latest 180-day insider tape.

Acquisitions / disposals over the latest 180 days. Insider activity is context, not a stand-alone signal.
News sentiment49/100

Weighted news tone is neutral across 51 relevant articles.

9 positive · 34 neutral · 8 negative
Patient CapitalQuiet

Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.

No recent buy signal
06 · Catalysts and risk

What can move the shares—and how volatile the path has been

Event timing, options-implied movement, drawdown, and weekly return distribution frame the risk around the current setup.

Next earnings12dNext report is scheduled for 13 Aug 2026; event risk rises as the date approaches.
Options expected move24.3%Nearest-chain priced movement where available.
52-week drawdown-14.9%Distance below the 52-week high.
13-week volatility7.3%Standard deviation of weekly returns.

Weekly gains and losses

Latest 26 completed weeks

Each bar is one week. Gains rise above the zero line; losses fall below it. Taller bars mean a larger weekly move.

Weeks higher14 of 2612 weeks finished lower.
Best week+14.1%Week of 3 Jul.
Worst week-13.6%Week of 24 Jul.
Latest week+6.1%Week of 31 Jul.

Shape of recent returns

Strong gains9
Modest gains5
Flat weeks0
Modest losses7
Sharp losses5
Recent vol7.3%13-week weekly-return volatility.
Base vol6.8%52-week weekly-return volatility.
Up/down split26/26Count of positive and negative weeks in the 52-week window.
Average skew5.4% / -5.0%Average positive week versus average negative week.
07 · Sector and peer context

Is this stock leading—or simply moving with its group?

Sector and industry breadth distinguish company-specific strength from a broad group move.

08 · Evidence and weekly data

The underlying research record

Every top-level statement above should be traceable to a stored market, fundamental, event, or positioning observation.

Weekly tape61/100

Trend, activity pressure, participation, and risk combine to a 61/100 tape read.

 Indicator analysis77/100

Latest 12-week confirmation: trend 12/12, activity pressure 12/12, relative leadership 5/12.

Activity pressure 0.79; No reversal markers Factors59/100

O'Shaughnessy factor stack blends value, quality, momentum, and confidence.

Buyback Yield rank 80; Small Cap Core rank 65 SVQF97/100

Value and quality alignment from the Sharemaestro SVQF framework.

Composite rank 20.0 of 726 Patient CapitalQuiet

Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.

No recent buy signal Options60/100

ABEO shows mixed options pressure with a 43/100 conviction score, put-call volume ratio of 1.20, expected move of 24.3%, and Sharemaestro trend signal active.

Mixed · Options-market disagreement · Expected move 24.3% Sentiment49/100

Weighted news tone is neutral across 51 relevant articles.

ABEO|Abeona Therapeutics Inc|Price:6.240|Chg%:+0.220 Insiders0 / 20

0 acquisitions and 20 disposals in the latest 180-day insider tape.

 Earnings12d

Next report is scheduled for 13 Aug 2026; event risk rises as the date approaches.
WeekCloseReturnTrend LineFair ValuePressureLeadershipVolumeTrend
31 Jul 20266.42 USD6.1%5.45 USD5.44 USD1.366.864.8MOn
24 Jul 20266.05 USD-13.6%5.41 USD5.42 USD1.490.726.2MOn
17 Jul 20267.00 USD0.3%5.39 USD5.41 USD1.5713.995.7MOn
10 Jul 20266.98 USD9.1%5.33 USD5.39 USD1.418.539.1MOn
3 Jul 20266.40 USD14.1%5.27 USD5.37 USD1.131.157.0MOn
26 Jun 20265.61 USD-2.8%5.22 USD5.35 USD0.88-10.897.6MOn
19 Jun 20265.77 USD4.3%5.21 USD5.34 USD0.78-12.965.5MOn
12 Jun 20265.53 USD1.3%5.16 USD5.34 USD0.72-14.985.0MOn
5 Jun 20265.46 USD-5.5%5.13 USD5.33 USD0.81-14.864.0MOn
29 May 20265.78 USD6.2%5.08 USD5.32 USD1.01-14.833.1MOn
22 May 20265.44 USD-0.9%5.05 USD5.31 USD0.96-18.244.9MOn
15 May 20265.49 USD-6.9%5.05 USD5.29 USD0.90-17.367.9MOn
8 May 20265.90 USD8.7%5.05 USD5.28 USD0.74-12.207.2MOn
1 May 20265.43 USD0.7%5.03 USD5.26 USD0.38-15.183.5MOn
How to use this report

This is a completed-week research summary. It explains the available evidence and its conflicts; it does not predict a guaranteed outcome or replace your own risk assessment. Fundamental figures may refer to an earlier financial reporting period, which is shown above.